SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

A strong quarterly earnings report and ambitious AI-compute expansion outlook are fueling bullish interest, while traders debate the spending plans, valuation, and potential Tesla merger. The large share unlock and profit-taking are tempering enthusiasm, with some traders viewing the added supply as a risk to the post-earnings rally.

Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 is headquartered in New York, NY.

Skydance Corp. - Ordinary Shares - Class B

The distribution and separate trading of long-dated warrants has driven sharp price swings and confusion over whether the share-price drop was mainly a mechanical adjustment or a loss in value. Some holders say the shares and warrants should be considered together, while skeptics point to dilution and the heavy debt from the Warner Bros. Discovery deal.

Strive, Inc. engages in the provision of an asset management Bitcoin treasury. It is focused on maximizing value for shareholders, accumulating bitcoin and outperforming bitcoin over the long run. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani, and Kyle Fairbanks on March 9, 2022 and is headquartered in Dallas, TX.

Strive Inc. - Ordinary Shares - Class A

Strive Inc.

Strives expanded Bitcoin treasury and the closing/listing of its SATS preferred offering are fueling attention, with bulls viewing the proceeds as capital for further Bitcoin purchases. The rally is drawing enthusiasm, while skeptics warn that the high dividend burden and potential share issuance could weigh on common shareholders.

Lam Research Corp. engages in the design, manufacture, marketing, refurbishment, and provision of semiconductor processing equipment used in the fabrication of integrated circuits. It operates through the following geographical segments: United States, China, Europe, Japan, Korea, Southeast Asia, and Taiwan. The company was founded by David K. Lam in 1980 and is headquartered in Fremont, CA.

Lam Research Corp.

Lam Research is drawing attention ahead of its earnings report, with traders debating whether the recent selloff reflects pre-report profit-taking or a possible leak; claims of leaked results remain speculation. Some see the pullback as a buying opportunity, while others are wary of further downside and the options-implied move.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Metas quarterly earnings are the dominant focus, with traders watching AI spending guidance and whether the Muse rollout can show traction and justify the investment. Views are split: bulls expect AI momentum to support growth, while bears worry that rising capex, weaker cash flow and a New Mexico privacy ruling could weigh on the stock.

Six Flags Entertainment Corp. engages in operating amusement parks in North America. It operates amusement parks, water parks, and resorts. The company is headquartered in Charlotte, NC.

Six Flags Entertainment Corp.

Six Flags Entertainment Corp

Six Flags is under pressure after Mizuho cut its outlook, amid continued fallout from a fatal roller-coaster accident, precautionary ride closures, and fresh safety concerns. Bears worry about reputational damage, legal exposure, and the companys debt, while some traders view the selloff as overdone and point to short-squeeze potential.

JD.com, Inc. is a technology-driven E-commerce company, which engages in the sale of electronics products and general merchandise products, including audio, video products, and books. It operates in the following segments: JD Retail, JD Logistics, and New Businesses. The JD Retail segment offers online retail, online marketplace, and marketing services. The JD Logistics segment includes internal and external logistics businesses. The New Businesses segment is composed of JD Property, Jingxi, overseas businesses and technology initiatives. The company was founded on June 18, 1998, by Qiang Dong Liu and is headquartered in Beijing, China.

JD.com Inc - ADR

JD is drawing attention after its latest earnings report showed a revenue decline but improved profitability and cash flow, yet shares sold off sharply. Traders are debating whether the drop is an overreaction to otherwise solid results or reflects weak Chinese consumer demand and persistent pressure on the companys growth.

Icahn Enterprises LP is a holding company. It operates through the following segments: Investment, Automotive, Energy, Food Packaging, Real Estate, Home Fashion, Pharma, and Holding Company. The Investment segment consists of various private investment funds. The Automotive segment holds ownership in Icahn Automotive Group, LLC. The Energy segment refers to petroleum refining and marketing businesses. The Food Packaging segment involves the production and sale of cellulosic, fibrous, and plastic casings for the processed meat and poultry industry. The Real Estate segment offers rental real estate, property development, and resort activities. The Home Fashion segment deals with manufacturing, sourcing, marketing, distributing, and selling home fashion consumer products. The Pharma segments operate through Vivus, Inc., a specialized pharmaceutical company. The Holding Company segment manages acquisition and investment in operating businesses. The company was founded on February 17, 1987 and is headquartered in Sunny Isles Beach, FL.

Icahn Enterprises L P - Unit

Icahn Enterprises, L.P.

IEP is drawing attention amid a steep selloff and concerns about potential hedging losses, debt maturities, and whether its distribution is sustainable ahead of earnings. Holders are frustrated by Icahns limited communication, while some bullish traders point to IEPs CVR Energy stake and speculate about a short squeeze or a rebound.

United Airlines Holdings, Inc. is a holding company, which engages in the provision of transportation services. It operates through the following geographical segments: Domestic, Atlantic, Pacific, and Latin America. The company was founded on December 30, 1968 and is headquartered in Chicago, IL.

United Airlines Holdings Inc

Uniteds quarterly earnings miss and sharply lower fourth-quarter profit guidance, driven by elevated fuel costs, are prompting debate as shares rally despite the weak outlook. Traders are weighing margin pressure against record revenue, resilient travel demand and expectations for continued revenue growth.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor is drawing attention ahead of an FDA decision on deramiocel for Duchenne muscular dystrophy, particularly the narrowed application focused on upper-limb function and the HOPE-3 data. Traders are divided: some see a path to approval, while others cite the prior advisory committee vote and disputed statistical analyses as risks; the uncertainty is fueling volatile trading and speculation about short-selling pressure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BLCO Stock Drops After-Hours — Bausch + Lomb Halts Glaucoma Eye Drop Program After Trial Failure

Equity

After 28 days of treatment, BL1107 did not meet its main goal of improving visual field scores in a study. 


STLA Stock Pares Loses: Unveils €190 Billion 2030 Revenue Target 

Stellantis is looking to bring €190 billion in revenue from 2030, compared to €154 billion reported in 2025.


Shell Stock Hits 52-Week High – Here’s Why

Rise in oil prices amid the ongoing conflict in the middle-east has spiked Brent crude and other energy product prices. 


Novo Nordisk To Launch Ozempic Pills Following Flat Growth In Diabetes Segment In 2025

The Ozempic pill will be launched in Q2 2026 and be available in doses 1.5 mg, 4 mg, and 9 mg.


Novo Nordisk Shares Tumble On 2025 Earnings Miss, Weak Sales Forecast And Competition Concerns

The drugmaker now expects fiscal 2026 adjusted sales down 5% to 13%.


Why Bitfarms Stock Is Down After Hours?

Keefe Bruyette downgraded Bitfarms to ‘Market Perform’ from ‘Outperform’. 


Novo Nordisk In Green After Oral Wegovy Clocks Over 18K Prescriptions In A Week

Reuters reported on Friday, citing IQVIA data shared by analysts, that Novo’s weight-loss pill was prescribed 18,410 times in the week ended January 16.


BHC Stock Plummets On Failed Liver Cirrhosis Trial: Retail Says ‘Lost Battle But Not The War’

The failed clinical program evaluated rifaximin SSD for the delay of the first episode of hepatic encephalopathy (HE) in adults with liver cirrhosis who experienced no prior episodes.


Novo Nordisk Inks Deal With Canada’s Aspect Biosystems To Find More Diabetes Meds Besides Ozempic

Novo and Aspect have been collaborating since 2023 to develop cellular medicines, and said that the new partnership phase builds on the momentum achieved in the existing collaboration.


Genmab Stock Drops On Mixed Results From Late-Stage Trial Of Lymphoma Drug

Epcoritamab demonstrated an improvement in progression-free survival in certain patients with relapsed or refractory diffuse large B-cell lymphoma, the company said.


Dimensional ETF Trust - Dimensional World ex U.S. Core Equity 2 ETF

Neutral Sentiment

<ul class="summary-bullets"><li>Instead of pursuing the eye drop further in glaucoma, Bausch + Lomb will focus on developing a sustained-release implant version of the same drug candidate for geographic atrophy.&nbsp;</li><li>Clinical trials for that program are expected to begin in 2028.</li><li>Following the BL1107 topical setback, Bausch + Lomb’s most advanced pharmaceutical programs are now the dual-action dry eye drop and BL1332 for ocular pain.&nbsp;</li></ul>&nbsp;Shares of Bausch + Lomb (BLCO) fell 4% after hours on Thursday after the company said that its experimental glaucoma treatment BL1107 failed to improve vision in a mid-stage clinical trial, prompting the company to stop development of the drug as a daily eye drop.<h2 class="st-heading-2">Trial Results</h2>The randomized, double-masked study enrolled 159 patients with glaucoma or high eye pressure. After 28 days of treatment, BL1107 did not meet its main goal of improving visual field scores, which measure peripheral vision. Key secondary measures of vision improvement also fell short.The drug, however, did succeed in lowering eye pressure, meeting one secondary goal. Safety results were consistent with earlier studies, with no new concerns identified, the company said.Bausch + Lomb has decided not to move forward with BL1107 as a topical eye drop for glaucoma. The company noted that an earlier, smaller study had shown promising vision improvements, but the larger mid-stage trial did not confirm those findings.<h2 class="st-heading-2">Executives React</h2>“Success in drug development is based on a portfolio, not a single program,” said Yehia Hashad, Executive Vice President of R&amp;D and Chief Medical Officer. “Not every program will succeed, but every study helps us make smarter decisions.”Following the BL1107 topical setback, Bausch + Lomb’s most advanced pharmaceutical programs are now the dual-action dry eye drop and BL1332 for ocular pain, both with data readouts expected in the second half of 2026.Instead of pursuing the eye drop further in glaucoma, Bausch + Lomb will focus on developing a sustained-release implant version of the same drug candidate for geographic atrophy, an advanced form of dry age-related macular degeneration, the company said. Clinical trials for that program are expected to begin in 2028.<h2 class="st-heading-2">How Did BLCO Retail Traders React?</h2>On Stocktwits, retail sentiment around BLCO stock stayed within the ‘neutral’ territory while message volume fell from ‘high’ to ‘normal’ levels.A Stocktwits user dismissed the company pipeline as the “worst.”<stembedurl>https://www.stocktwits.com/TickrTalk0007/message/658547774</stembedurl>Another termed the Thursday announcement a “clean negative readout.”<stembedurl>https://www.stocktwits.com/OttoReed328/message/658705745</stembedurl><a href="https://stocktwits.com/symbol/BLCO">BLCO stock</a> has fallen 2% year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/spacex-chief-elon-musk-says-anthropic-is-clear-ai-leader-vows-not-to-sabotage-compute-deal-despite-rivalry/cZmYODsR7nC">SpaceX Chief Elon Musk Says Anthropic Is ‘Clear AI Leader’ — Vows Not To Sabotage Compute Deal Despite Rivalry</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of eye health company Bausch Lomb Corporation is displayed on a smartphone in front of abstract background on computer screen. (Photo Illustration by Timon Schneider/SOPA Images/LightRocket via Getty Images)

After 28 days of treatment, BL1107 did not meet its main goal of improving visual field scores in a study. 

Bausch + Lomb Corp.

Double beat (rev + EPS)

Revenue beat, EPS miss

EPS beat, revenue miss

Double miss

Meta ($META) reports earnings after the close today. What do you expect?

Stocktwits

) reports earnings after the close today. What do you expect?

Current Price	$36.76
Prev Close	$36.54
Open	$36.69
Dividend Yield	N/A
50-Day Moving Average	$37.63
Beta	N/A
Avg. Volume	672,346.37
PE Ratio	N/A

52-Week High	$38.74
52-Week Low	$30.81
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

DFAX Fundamentals